What is Alopexx?
Alopexx is an investment, management, and development company focused on health care opportunities
In The Press
Valerion Therapeutics (formerly 4s3 Bioscience, Inc.) Secures $20M in Series A Financing
Medford, MA, March 5, 2012 — 4s3 Bioscience, Inc. (4s3), a privately-‐held bio therapeutics company focused on developing genetic disease therapies for orphan neuromuscular disorders announced today the closing of a $20 million Series A financing with KLP Enterprises, LLC (KLP). KLP’s subsidiary, Alopexx Enterprises, LLC (Alopexx), will work with 4s3 to build and manage… Read More »
Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement Provenance secures $8M project financing for the continued clinical development of the anti-cancer therapeutic, DI-Leu16-IL2.
Waltham, MA, December 22, 2011 /PRNewswire/ — Provenance Biopharmaceuticals Corp. (“Provenance”) announced today the closing of an $8 million financing arrangement with Alopexx Enterprises, LLC for the continued development of anti-cancer therapeutic, DI-Leu16-IL2. DI-Leu16-IL2 is among a class of molecules called immunocytokines that are being developed for the treatment of various forms of cancer. Immunocytokines, combine the… Read More »
Alopexx announced today that sanofi-aventis exercises option to acquire exclusive and worldwide rights to Alopexx Pharmaceuticals’ novel human monoclonal antibody targeting infectious diseases
- Novel antibody targeted against methicillin-resistant S. aureus ( MRSA ) and other serious infectious diseases- Cambridge, MA , October 27, 2010 – sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has recently elected to exercise its option to acquire an exclusive and worldwide license of Alopexx’s F598 antibody following review of the results generated during its… Read More »